Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cantharidin Sodium Vitamin B6 Injection (DCVB6) is a traditional Chinese medicine (TCM) preparation approved in China for the treatment of various malignancies, including lung cancer and primary liver cancer. The formulation combines disodium cantharidinate, a derivative of cantharidin extracted from Chinese blister beetles (*Mylabris phalerata* and *Mylabris cichorii*), with vitamin B6 (pyridoxine). Disodium cantharidinate acts as an antineoplastic agent by inhibiting protein phosphatase 2A (PP2A), which induces tumor cell apoptosis, enhances immune function, and inhibits metastasis. Vitamin B6 is included in the preparation to mitigate the side effects associated with cantharidinate, particularly its potential for urinary tract irritation and other toxicities. It is primarily utilized as an adjunctive therapy alongside conventional chemotherapy regimens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on disodium cantharidinate + pyridoxine.